Edition:
United States

Shire PLC (SHPG.OQ)

SHPG.OQ on NASDAQ Stock Exchange Global Select Market

171.25USD
20 Jul 2018
Change (% chg)

$-1.73 (-1.00%)
Prev Close
$172.98
Open
$172.62
Day's High
$172.92
Day's Low
$170.93
Volume
205,129
Avg. Vol
454,953
52-wk High
$177.51
52-wk Low
$123.73

Summary

Name Age Since Current Position

Susan Kilsby

59 2014 Non-Executive Chairman of the Board

Flemming Ornskov

60 2013 Chief Executive Officer, Executive Director

Thomas Dittrich

54 2018 Chief Financial Officer, Executive Director

Joanne Cordeiro

60 2017 Chief Human Resource Officer

Andreas Busch

54 2018 Chief Scientific Officer, Head - Research and Development

William Mordan

48 2015 General Counsel, Company Secretary

Perry Sternberg

49 2016 Head - U.S. Commercial

Kim Stratton

56 2016 Head - International Commercial

Matthew Walker

54 2016 Head - Technical Operations

Olivier Bohuon

59 2018 Senior Non-Executive Independent Director

Ian Clark

57 2017 Non-Executive Independent Director

Gail Fosler

70 2016 Non-Executive Independent Director

Steven Gillis

64 2012 Non-Executive Independent Director

Sara Mathew

62 2015 Non-Executive Independent Director

Albert Stroucken

70 2016 Non-Executive Independent Director

Christoph Brackmann

2018 Interim Head of Investor Relations

Biographies

Name Description

Susan Kilsby

Ms. Susan Saltzbart Kilsby serves as Non-Executive Chairman of the Board of Shire Plc. Susan served as an independent Non-Executive Director prior to her appointment as Chairman on April 29, 2014. Susan brings to her role extensive M&A and finance experience having enjoyed a distinguished global career in investment banking. She held senior positions with The First Boston Corporation, Bankers Trust, Barclays de Zoete Wedd and most recently Credit Suisse where she was Chairman of the EMEA Mergers & Acquisitions team until 2009, and a part-time senior advisor until 2014. Susan is also a former Director of Keurig Green Mountain, Inc., L’Occitane International S.A. and Coca-Cola HBC AG. She holds a BA in Economics and a MBA. She also worked with BBA Aviation plc (Non- Executive Director), Goldman Sachs International (Non-Executive Director) and Fortune Brands Home & Security, Inc. (Non-Executive Director).

Flemming Ornskov

Dr. Flemming Ornskov, M.D., MBA, MPH, serves as Chief Executive Officer, Executive Director of Shire Plc. Flemming served as Chief Executive Officer Designate prior to his appointment as Chief Executive Officer on April 30, 2013. Flemming brings to his role his operational and medical knowledge and his extensive international, strategic and operational experience in the pharmaceutical sector. He formerly held the positions of Non-Executive Chairman of Evotec AG and Non-Executive Director of PCI Biotech Holding ASA. From 2010 to 2012 he was Chief Marketing Officer and Global Head, Strategic Marketing for General and Specialty Medicine at Bayer. From 2008 to 2010 Flemming served as Global President, Pharmaceuticals and OTC at Bausch & Lomb, Inc. He also served as Chairman, and later as President and Chief Executive Officer, of Life-Cycle Pharma A/S from 2006 to 2008, and as President and Chief Executive Officer of Ikaria, Inc. from 2005 to 2006. Earlier in his pharmaceutical career Flemming held roles of increasing responsibility at Merck & Co., Inc. and Novartis AG, following a distinguished period spent in hospitals and academic medicine. Flemming received his MD from the University of Copenhagen, his MBA from INSEAD and his Master of Public Health from Harvard University.

Thomas Dittrich

Mr. Thomas Dittrich serves as Chief Financial Officer, Executive Director of the Company effective on March 19, 2018. Thomas will bring to his role his finance and leadership experience. He previously served as Chief Financial Officer and a member of the Executive Committee at Sulzer Ltd. Thomas joined Sulzer in August 2014, serving as Chief Executive Officer ad interim between August 2015 and December 2015. Prior to joining Sulzer, he served as Vice President, Finance Corporate Planning and Chief Accounting Officer of Amgen Inc. between 2010 and 2014. Between 2006 and 2010, Thomas was Vice President, Finance and Chief Financial Officer of Amgen International. He also spent eight years with Dell where he held various finance and general manager roles. Earlier in his career, Thomas worked at Booz & Co and Helbing Management Consulting AG in operational and merger and acquisition roles, respectively. He holds a Master of Science in Finance, Accounting and Business Administration from the University of St. Gallen and a Master of Science in Mechanical Engineering from the Technical University Munich.

Joanne Cordeiro

Ms. Joanne Cordeiro is Chief Human Resource Officer of the Company. Joanne joined Shire in 2011 and serves as Chief Human Resources Officer. She previously held various Human Resources management and executive search roles at Teradyne Inc., Covansys Corporation, Avid Technology, Inc. and Sybase Inc. Joanne holds a Bachelor’s degree in Marketing from Northeastern University.

Andreas Busch

Prof. Dr. Andreas Busch, Ph D., serves as Chief Scientific Officer, Head - Research and Development of the Company. Dr. Busch is currently Head of Drug Discovery and a member of the Executive Committee for the Pharmaceuticals division of Bayer, where he leads a team of approximately 3,300 researchers. During his 13 years at Bayer, he has held roles of increasing responsibility within the company, including Senior Vice President, Head Discovery Europe at Bayer HealthCare and Executive Vice President, Global Head Drug Discovery. Dr. Busch was responsible for the Schering drug discovery integration, the overall R&D strategy and enforced the improvement of Bayer's research productivity. Prior to joining Bayer, Dr. Busch was Global Head of Cardiovascular Research at Hoechst and Sanofi-Aventis. Prior to that, he led independent research groups as a Heisenberg Fellow at the University of Tübingen and the Max-Planck-Institute for experimental Medicine in Göttingen. Dr. Busch is a member of several Supervisory and Scientific Boards, including the German Cancer Research Center, the University of Tübingen, the Max-Delbrück-Center and the Max-Planck-Institute of Molecular Genetics. He also holds the title of Extraordinary Professor of Pharmacology at the Johann Wolfgang Goethe-University in Frankfurt, Germany. Dr. Busch received his license to practice Pharmacy and Ph D in Pharmacology from the Johann Wolfgang Goethe-University Frankfurt. He is the author of some 400 publications and abstracts, and received the prestigious Sir Bernard Katz and Franz Volhard Awards for his work on renal and cardiac ion channels and transporters.

William Mordan

Mr. William Mordan serves as General Counsel, Company Secretary of the Company. Bill joined Shire in 2015 and serves as General Counsel and Company Secretary. He previously served as General Counsel and Company Secretary at Reckitt Benckiser Group plc in the UK, prior to which he held various roles at Procter & Gamble in the U.S., Mexico and Brazil. Earlier in his career, Bill served as a clerk in the U.S. Court of Appeals for the Sixth Circuit. He holds a Juris Doctor degree from the University of North Carolina.

Perry Sternberg

Mr. Perry Sternberg serves as Head - U.S. Commercial of the Company. Perry joined Shire in 2013 and is Head of U.S. Commercial. He was previously Vice President & General Manager, U.S. & Canada Pharmaceuticals at Bausch & Lomb. Prior to that, Perry held various roles at Novartis Ophthalmics, Novartis Pharmaceuticals and Merck & Co., Inc. He holds a Bachelor’s degree in Animal Bioscience from Pennsylvania State University.

Kim Stratton

Ms. Kim Stratton serves as Head - International Commercial of the Company. Kim joined Shire in 2013 and is Head of International Commercial. She was previously Global Head of Group Country Management & External Affairs for Novartis. Prior to that, Kim held various roles of increasing responsibility at Novartis, Bristol Myers Squibb and AstraZeneca. She qualified as a State Registered Nurse at the Royal North Shore Hospital, Australia.

Matthew Walker

Mr. Matthew Walker, BSCHE serves as Head - Technical Operations of the Company. Matt joined Shire in 2016 and is Head of Technical Operations. Previously he worked at Pfizer for over 20 years in engineering and operations roles within the supply organization — his last two positions being Operations Lead for Sterile Injectables and Operations Lead for Biologics/Vaccines. Prior to Pfizer, Matt worked as a Project Director for John Brown Engineering and Construction. He holds a Bachelor’s degree in Chemical Engineering from Tufts University.

Olivier Bohuon

Mr. Olivier Bohuon is Senior Non-Executive Independent Director of the Company. He is currently serves as Non-Executive Independent Director of the Company. Olivier brings to the Board his extensive international business and leadership experience gained through roles held in pharmaceutical and healthcare companies across Europe, the Middle East and the U.S. He is to be appointed Senior Independent Director with effect from the conclusion of the 2018 Annual General Meeting. He currently holds the position of Chief Executive Officer at Smith & Nephew plc, having previously served as Chief Executive Officer and President of Pierre Fabre Group and as President of Abbott Pharmaceuticals; a division of U.S.-based Abbott Laboratories. Olivier also held diverse commercial leadership positions at GlaxoSmithKline and its predecessor companies in France. He holds an MBA from HEC Paris School of Management and a doctorate in Pharmacy from the University of Paris. He has been with Smith & Nephew plc (Chief Executive Officer), Biotech Promise (Non-Executive Director) and Virbac SA (Non-Executive Director).

Ian Clark

Mr. Ian T. Clark serves as Non-Executive Independent Director of the Company. Mr. Ian brings to the Board his extensive leadership and biotechnology sector experience. Ian served as Chief Executive Officer and Director of Genentech Inc. (part of the Roche Group) and Head of North American Commercial Operations for Roche until 2016. From 2003 to 2010 he held the positions of Head of Global Product Strategy and Chief Marketing Officer, Executive Vice President — Commercial Operations and Senior Vice President and General Manager — BioOncology at Genentech. Prior to this Ian was appointed President of Novartis Canada, having previously served as Chief Operating Officer for Novartis United Kingdom. He also held various sales and marketing roles at Sanofi and Ivax. Ian is a former Non-Executive Director of TerraVia Holdings Inc. and Kite Pharma, Inc. Ian holds a Bachelor’s degree in Biological Sciences from the University of Southampton. He has been with Agios Pharmaceuticals, Inc. (Non-Executive Director), Corvus Pharmaceuticals, Inc. (Non-Executive Director) and Gladstone Institute (Member).

Gail Fosler

Ms. Gail D. Fosler is Non-Executive Independent Director of the Company. Gail brings to the Board her commercial, public policy and economics experience. She is President of The GailFosler Group LLC, a strategic advisory service for global business leaders and public policy makers, which she has led since 2010. Prior to this, Gail spent over 20 years at The Conference Board where she served as President and Trustee, Executive Vice President and Chief Economist. Gail is a former Director of Baxter International, Inc., Baxalta, Inc., Swiss Reinsurance America Corporation and Caterpillar, Inc. She holds a Master of Business Administration degree in Finance from New York University and a Bachelor of Arts Degree in Economics from the University of Southern California. She has been with The GailFosler Group LLC (President) and Deschner Corporation (Non- Executive Director and Chair).

Steven Gillis

Dr. Steven H. Gillis, Ph.D. is Non-Executive Independent Director of Shire plc., since October 1, 2012. Steven brings to the Board his extensive technical and scientific knowledge and commercial experience. He is currently a Managing Director at ARCH Venture Partners; a provider of venture capital for technology firms. Prior to this Steven was a founder and Director of Corixa Corporation, acquired by GlaxoSmithKline in 2005, and before that a founder and Director of Immunex Corporation. An immunologist by training, Steven has authored more than 300 peer-reviewed publications in the areas of molecular and tumor immunology. He is credited as being a pioneer in the field of cytokines and cytokine receptors, directing the development of multiple marketed products including Leukine, (GM-CSF), Prokine (IL-2) and Enbrel (soluble TNF receptor-Fc fusion protein) as well as the regulatory approval of Bexxar (radiolabeled anti-CD20) and the novel vaccine adjuvant, MPL. Steven received his BA from Williams College and his PhD from Dartmouth College. Key appointments are ARCH Venture Partners (Managing Director), Pulmatrix, Inc. (Non- Executive Director), PhaseRx Inc. (Chairman and Non-Executive Director) and VBI Vaccines Inc. (Chairman and Non-Executive Director).

Sara Mathew

Ms. Sara Mathew is Non-Executive Independent Director of the Company. Sara brings to the Board her financial, strategic and technological experience, having held various corporate leadership roles. She served as Chairman, President and Chief Executive Officer of Dun & Bradstreet, Inc. until 2013, having spent 12 years at the company. Prior to this, Sara worked for 18 years at Procter & Gamble where she held a variety of global finance and management positions including Vice President, Finance — Australia, Asia and India. She is also a former Non-Executive Director of Avon Products, Inc. Sara received her MBA from Xavier University, her Accounting degree from the Institute of Cost & Works Accountants and her Bachelor’s degree in Physics, Mathematics and Chemistry from the University of Madras. She has been with Campbell Soup Company (Non-Executive Director) and Freddie Mac (Non-Executive Director).

Albert Stroucken

Mr. Albert P. L. Stroucken is Non-Executive Independent Director of the company. He brings to the Board his manufacturing, commercial and international experience. He served as Executive Chairman of Owens-Illinois, Inc. until 2016, having served as Chairman, President and Chief Executive Officer from 2006 until 2015. From 1998 to 2006 Al held the position of President and Chief Executive Officer of H.B. Fuller Company, adding the role of Chairman in 1999. He served as General Manager of the Inorganics division of Bayer AG from 1997 to 1998, serving as Executive Vice President and President of the Industrial Chemicals division of Bayer Corporation from 1992 to 1997. Al served as a Non-Executive Director of Baxalta Incorporated until 2016. Key appointments are Baxter International, Inc. (Non-Executive Director).

Christoph Brackmann